Diddent post at BULL
var lnb_S=1;var lnb_I="VID=704
1&m_PR=40&LHM=1&LCBURL=ht
tp://ragingbull.lycos.com%2fmboard%2fpost%2ecgi&SCBURL=ht
tp://ragingbull.lycos.com/mboard/rbreg.cgi";
[]
[] [] [] [] []
[] [] ENTER SYMBOL
Find symbol
[]
[] Account Management
Upgrade Subscription []
[] []
[] [] []
[]
[] [] Board Directory | Member Forums | Most Active Boards | Rules of the Road | Help & Feedback
[] []
[]
[] [] []
IAMR (RB: IAMR)
[]
[] Successful Posting!
Your post (Msg. 5116) is now on the IAMR board.
• Return to the IAMR message list
(This page will redirect)
[]
You posted:
By: Chucka
26 Aug 2002 6:38 PM EDT Msg. 5116 of 5116
The Canadian Market Forces ( thanks be we are on the PINKS here ) GYPSY sWaPs: In a message dated 8/25/02 6:54:08 PM Eastern Daylight Time, Chucalo writes: Subj:Question to get to them: answer Date:8/25/02 6:54:08 PM Eastern Daylight Time From:Chucalo To:Chucalo1 BCC:.com Analyst Reports - ... Mr. Sam Parks. May 10, 1999. Midland Walwyn, Michael Curran. Gypsy Swap to Generate Funds for Dolores Feasibility. December 1998. The ... NOT available: "' May 10, 1999Midland Walwyn, Michael Curran"Gypsy Swap to Generate Funds for Dolores Feasibility" "" minefinders.com aolsearch.aol.com and ANGLAISE (Page 1) - ... Here, the rich man of yesteryear speaks of his youth to the man who has always been poor; the travelling show man and gypsy swap the latest news about the ... theatre-odeon.fr News - Cardiocomm Solutions Inc. - ... Mr. Martin sold 500,000 shares today as part of a gypsy swap, under which he agreed to purchase an additional 500,000 shares. The ... cardiocomm.com "" Press Release CardioComm Announces Brokered Private Placement VICTORIA, B.C., April 17, 2002 - CardioComm Solutions Inc. (CDNX:CCG) (the "Company", "CardioComm") is pleased to announce that subject to regulatory approval, the Company has agreed to a brokered private placement with Desjardins Securities for 3,500,000 shares at a price of $0.20 per for gross proceeds of C$700,000. A commission will be payable to Desjardins.As part of this financing, Mr. Stephen Martin, CardioComm's President & CEO has subscribed for shares under the private placement. Mr. Martin sold 500,000 shares today as part of a gypsy swap, under which he agreed to purchase an additional 500,000 shares. The proceeds will be used for general working capital.About CardioComm Solutions Inc. CardioComm's patented and proprietary technology is used in products for the recording, viewing, analyzing and storing of electrocardiograms (ECGs), for diagnosis and management of cardiac patients. CardioComm has achieved its technical goals of improved access and communication through the development of a real-time ECG viewer. CardioComm is the first company to provide a real-time means of viewing ECGs over a network (LAN, WAN or Internet). This tool enables ECGs to be viewed and controlled live, by physicians, over a global virtual healthcare network. This technology is marketed as Global ECG Management System (GEMS™) and GlobalCardio™. CardioComm's software products have been cleared for sale in the United States by the U.S. Food and Drug Administration. The Company has both ISO 9001 and EN 46001 certifications.For further information on the Company's software products please contact Mr. Stephen Martin at (250) 744-1822, EXT 243 or visit the Company's website at cardiocomm.com. On behalf of the Board of Directors of CardioComm Solutions Inc.: Stephen R. Martin, President & CEO "" Chucka- this has had nothing to do with IAMR, but Hadesdog last Biting POST is on the Market Distortion SUBJECT that I am collection info on to study, I heard of GYPSY SWAPS befor, and they appear to be a common thing. I am one of the Original 6 yrs ago investors in Cardiome as it used to be clled Nortran. PS- I wrote this Bio Tect at NOON, FDA approvals are more better than some DUMB AUDITOR going out to look at a mine work, CAN MET STANDARDS and Regulations now are different in MINING with EXACT USA and CN standards..now NEW LAWS govern ..old are just that: "" To:Sean Janzen who wrote (1180) From: Chuca Marsh Monday, Aug 26, 2002 12:43 PM Respond to of 1184 Hi George YOU are still posting but Sean is not LOOK: Thought of Cardiome # 1235 is still intrails: OK Nortran LOL] : ""A plain-text copy of the "SCIENCE News This Week" section has been appended below. If you no longer wish to receive these messages, you may modify your "Contents Awareness" profile at: sciencemag.org ----------------------------------------------------------------- SCIENCE News This Week August 23 2002, 297 (5585) NEWS OF THE WEEK ------------------- --------------------------------------------------------------------------- PHARMACOGENETICS: Gene Mutation May Boost Risk of Heart Arrhythmias (p. 1252) --------------------------------------------------------------------------- Jean Marx Researchers have already identified several mutant genes that cause rare and potentially fatal heart arrhythmias. Now, on page 1333, a team offers evidence that a different variation in one of those genes, dubbed SCN5A, might increase the risk of heart rhythm disturbances in members of the population at large, not just in those few people with the hereditary arrhythmias. The variant gene, found primarily in persons of African descent, isn't likely to cause problems on its own, but might in combination with certain medications, including some used to treat high blood pressure, that also raise the risk of heart arrhythmias. Full story at sciencemag.org "" and Cardiome's RSD1122 compound to be returned Cardiome Pharma Corp (2) COM Shares issued 28,280,598Mar 27 2002 close $ 2.86 Thursday March 28 2002News Release Mr. Bob Rieder reports CARDIOME ANNOUNCES RETURN OF RIGHTS TO RSD1122 Cardiome Pharma has received notice from AstraZeneca AB that AstraZeneca does not intend to proceed with clinical development of Cardiome's preclinical compound RSD1122. Under the terms of the licence agreement, AstraZeneca will return all rights and preclinical data associated with the compound to Cardiome. Cardiome will evaluate the AstraZeneca preclinical data and, following consultation with its board of directors and scientific advisory board, decide future plans for the preclinical drug candidate. "In light of our recent successes, this is somewhat disappointing to Cardiome," said Bob Rieder, Cardiome's president and chief executive officer. "However, our two unpartnered clinical programs are significantly more advanced, and therefore far more valuable to Cardiome, than the preclinical RSD1122 program. Our relationship with AstraZeneca remains positive and we continue to maintain a dialogue with them on other potential partnership opportunities." "As far as we know, AstraZeneca's decision regarding RSD1122 was based on difficulties associated with manufacturing and pharmacokinetic issues," stated Dr. Alan Ezrin, Cardiome's chief scientific officer. "Cardiome's atrial arrhythmia drug RSD1235 targets a different biological mechanism, has no significant manufacturing issues, and has pharmacokinetic properties compatible with acute and chronic management of atrial fibrillation." Cardiome is currently completing a 60-patient phase 2 clinical trial of RSD1235, for conversion of atrial arrhythmia to normal heart rhythm. The study is being conducted at 20 sites in the United States and Canada. Through its recent acquisition of Paralex, Inc., Cardiome is also developing oxypurinol for treatment of congestive heart failure. Cardiome intends to begin a phase 2 clinical trial with oxypurinol in the second half of 2002. WARNING: The company relies upon litigation protection for "forward-looking" statements. (c) Copyright 2002 Canjex Publishing Ltd. stockwatch.com old url (better for printing) Chucka "" I posted that at Lunchtime: Message 17919215 |
